Zydus Lifesciences to Acquire Assertio Holdings for $166.4 Million

Assertio Holdings, Inc. (ASRT) entered a merger agreement on May 13, 2026, to be acquired by Zydus Lifesciences for $166.4 million, after terminating its earlier merger with Garda Therapeutics.

Deal Structure:

Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences, will commence a tender offer to acquire all outstanding shares of Assertio common stock for $23.5 per share in cash, representing a premium of 4.21% from the stock’s last close.

Company Profile:

Assertio Holdings is a U.S.-based specialty pharmaceutical company that markets prescription medicines focused on pain, inflammation, neurology, and hospital care. Its portfolio includes products for arthritis, migraines, and acute pain management.

Zydus Lifesciences is an India-based pharmaceutical company engaged in the research, development, manufacturing, and sale of generic drugs, specialty medicines, vaccines, biosimilars, and consumer healthcare products. The company operates globally across therapeutic areas, including oncology, neurology, gastrointestinal, and infectious diseases.

Deal Details and Timeline:

The Assertio Board determined that Zydus’ offer qualified as a “Superior Proposal” and approved the termination of the Garda transaction.

Zydus paid to Garda a termination fee of $5.81 million.

The merger is expected to close in the second quarter of 2026.

Assertio received financial advice from Moelis & Co, while Gibson, Dunn & Crutcher acted as its legal advisor.

Deal Metrics:

For a more comprehensive understanding of the merger transaction, visit the Deal Metrics page at:

Deal Metrics for the acquisition of Assertio Holdings, Inc. (ASRT) by Zydus Worldwide DMCC

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart of the merger from announcement through eventual completion or failure.
• Key events as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
• News and SEC filings related to the merger.
• An archive of deal updates.
• And much more detailed information.

Disclaimer: Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article